Page 105 - 2021_07-Haematologica-web

Allograft and preemptive immuneintervention in CLL
manifestations of graft-versus-host disease in human recipients of marrow from HL-A- matched sibling donors. Transplantation. 1974;18(4):295-304.
24. Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15 (6):825-828.
25. Mantel N, Byar DP. Evaluation of response- time data involving transient states: an illus- tration using heart-transplant data. J Am Stat Assoc. 1974;69:81-86.
26. Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non- responder bias. Stat Med. 1984;3(1):35-44.
27. Kharfan-Dabaja MA, Kumar A, Hamadani M, et al. Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the guidelines com- mittee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2016;22(12):2117-2125.
28. Tournilhac O, van Gelder N, Dreger P, et al. The 10-years EBMT landscape of allogeneic hematopoietic cell transplantation (alloHCT) for chronic lymphocytic leukemia. 46th Annual Meeting of the European Society for Blood and Marrow Transplantation. Madrid, 2020
29. Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, ben- damustine, and rituximab for previously treated chronic lymphocytic leukaemia or
small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200-211.
30. Deng R, Gibiansky L, Lu T. Bayesian popu- lation model of the pharmacokinetics of venetoclax in combination with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from the Phase III MURANO Study. Clin Pharmacokinet. 2019;58(12):1621-1634.
31.O'Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131(17):1910-1919.
32. Mato AR, Thompson M, Allan JN, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018;103(9):1511- 1517.
33. Jain P, Thompson PA, Keating M, et al. Long- term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017;123(12):2268-2273.
34. Anderson M, Tam C, Lew TE, et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood. 2017;129(25):3362-3370.
35. Porter DL, Hwang W-T, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139
36. Turtle CJ, Hay KA, Hanafi LA, et al. Durable molecular remissions in chronic lymphocyt- ic Leukemia treated with CD19-specific
chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol. 2017;35(26):3010-3020.
37. Lemal R. Tournilhac O. State-of-the-art for CAR T-cell therapy for chronic lymphoid leukemia in 2019. J Immunother Cancer. 2019;7(1):202.
38.DregerP,GhiaP,ScheteligJetal.High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood. 2018;132(9): 892-902.
39. Krämer I, Stilgenbauer S, Dietrich S, et al. Allogeneic hematopoietic cell transplanta- tion for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017;130(12):1477-1480.
40.Link CS, Teipel R, Heidenreich F, et al. Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51(6):793-798.
41. Ryan CE, Sahaf B, Logan AC, et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia fol- lowing allogeneic HSCT. Blood. 2016;128(25):2899-2908.
42.Dreger P, Schetelig J, Andersen N, et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplanta- tion or novel agents? Blood. 2014;124(26): 3841-3849.
43. Hoffmann A, Dietrich S, Hain S, et al. Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-cen- ter, intent-to-treat analysis. Haematologica. 2019;104(7):e304-e306.
haematologica | 2021; 106(7)
1875